Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10741MR)

This product GTTS-WQ10741MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10741MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9937MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ9755MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ9855MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ14330MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ4518MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ4886MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ10845MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ3040MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW